Nucala

Nucala

mepolizumab

Manufacturer:

GlaxoSmithKline

Distributor:

Zuellig
/
Agencia Lei Va Hong
Concise Prescribing Info
Contents
Mepolizumab
Indications/Uses
Add-on treatment for severe refractory eosinophilic asthma in adults (for vial & pre-filled pen) & adolescents ≥12 yr (for pre-filled pen only).
Dosage/Direction for Use
Adult & adolescent ≥12 yr 100 mg SC once every 4 wk.
Contraindications
Special Precautions
Should not be used to treat acute asthma exacerbations. Asthma-related adverse events or exacerbations may occur. Abrupt discontinuation of corticosteroid after initiation of Nucala therapy is not recommended. Acute & delayed systemic reactions, including hypersensitivity reactions. Patients w/ pre-existing helminth infections. Pregnancy & lactation. Childn & adolescent <18 yr (for vial) or <12 yr (for pre-filled pen).
Adverse Reactions
Headache. Back pain; administration-related reactions, local inj site reactions, pyrexia; lower resp tract infection, UTI, pharyngitis; hypersensitivity reactions; nasal congestion; upper abdominal pain; eczema.
MIMS Class
Antiasthmatic & COPD Preparations
ATC Classification
R03DX09 - mepolizumab ; Belongs to the class of other systemic drugs used in the treatment of obstructive airway diseases.
Presentation/Packing
Form
Nucala powd for soln for inj 100 mg
Packing/Price
1's
Form
Nucala soln for inj 100 mg/mL
Packing/Price
1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in